# PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

> **NCT02864030** · PHASE4 · COMPLETED · sponsor: **Oncologia Medica dell'Ospedale Fatebenefratelli** · enrollment: 200 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Toxicity
- Neurotoxicity
- Drug Toxicity
- Adverse Drug Event

## Interventions

- **DRUG:** ERIBULIN MESYLATE

## Key facts

- **NCT ID:** NCT02864030
- **Lead sponsor:** Oncologia Medica dell'Ospedale Fatebenefratelli
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2018-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2021-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02864030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02864030, "PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02864030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*